Pub Date : 2026-01-14DOI: 10.1016/j.ajo.2026.01.015
Shinji Kakihara, Amani A Fawzi
{"title":"Comment on: Choroidal-derived intraretinal neovascularization compensates for diabetic retinopathy ischemia via dual-pathway remodeling post-pan-retinal photocoagulation.","authors":"Shinji Kakihara, Amani A Fawzi","doi":"10.1016/j.ajo.2026.01.015","DOIUrl":"10.1016/j.ajo.2026.01.015","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145987520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.ajo.2026.01.008
Angel Gao,Tasha Miller,Arturo Ortin-Martinez,Radha P Kohly
TOPICOphthalmology remains one of the least diverse medical specialties, with persistent racial and ethnic disparities throughout training and practice. This review examines experiences of individuals from underrepresented racial minorities (URiM) in ophthalmology within high-income countries, focusing on barriers to representation, discrimination, and equity initiatives.CLINICAL RELEVANCEIdentifying and addressing barriers faced by URiM in ophthalmology is essential to advancing workforce diversity, equitable patient care, and institutional inclusivity. Understanding where inequities persist can inform systemic interventions.METHODSA systematic review of the literature was conducted in MEDLINE, Embase, PsycINFO, CINAHL, Web of Science, and Cochrane Library from inception to November 2024. Eligible studies included English-language publications from 2000 onwards focusing on racial or ethnic minority individuals in ophthalmology. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale and Joanna Briggs Institute Checklist. Data were synthesized descriptively and thematically. The protocol was registered on PROSPERO (CRD42025640520).RESULTS41 eligible studies involving 500,823 responses were included. Most studies were cross-sectional, published after 2021 and conducted in the United States. Across all career stages, URiM individuals were underrepresented and faced structural barriers. In medical school, fewer URiM students pursued ophthalmology, citing lack of mentorship and role models. Minority representation among applicants has increased modestly, particularly among Hispanic students, though overall growth remains limited. During residency and fellowship, racial disparities persisted in research access, fellowship application outcomes, and interview offers. URiM trainees reported negative experiences related to program culture and inclusivity. In practice, racialized ophthalmologists reported higher discrimination rates, reduced advancement into leadership, and underrepresentation on faculty and editorial boards. While URiM match rates have improved, progress has been uneven. Asian representation has approached parity, while Black, Native American, and Pacific Islander individuals remain severely underrepresented. National ophthalmology mentorship programs have demonstrated high match success and participation. Residency programs that implemented structured interviews, holistic review and targeted equity strategies reported improved URiM representation, though implementation varied.CONCLUSIONRacial and ethnic disparities remain pervasive in ophthalmology. While overall progress has occurred, gains have been concentrated among Asian individuals. Coordinated systemic reforms are urgently needed for a more representative, inclusive, and supportive professional environment in ophthalmology.
主题眼科仍然是最不多样化的医学专业之一，在整个培训和实践中存在持续的种族和民族差异。本综述考察了高收入国家中代表性不足的少数民族（URiM）在眼科的经历，重点关注代表性障碍、歧视和公平倡议。临床相关性识别和解决URiM在眼科面临的障碍对于促进劳动力多样性、公平的患者护理和机构包容性至关重要。了解不平等存在的地方可以为系统性干预提供信息。方法系统回顾MEDLINE、Embase、PsycINFO、CINAHL、Web of Science和Cochrane Library自成立以来至2024年11月的文献。符合条件的研究包括2000年以来的英语出版物，重点关注眼科中的种族或少数民族个体。两位审稿人独立筛选研究，提取数据，并使用纽卡斯尔-渥太华量表和乔安娜布里格斯研究所检查表评估偏倚风险。对数据进行了描述性和主题性的综合。协议在PROSPERO上注册（CRD42025640520）。结果纳入41项符合条件的研究，涉及500,823项应答。大多数研究都是横断面的，在2021年之后发表，并在美国进行。在所有职业阶段，URiM个体的代表性不足，面临结构性障碍。在医学院，攻读眼科专业的URiM学生较少，理由是缺乏指导和榜样。申请人中少数族裔的比例略有增加，尤其是在西班牙裔学生中，尽管总体增长仍然有限。在住院医师和奖学金期间，种族差异在研究机会、奖学金申请结果和面试机会方面持续存在。URiM学员报告了与项目文化和包容性相关的负面经历。在实践中，种族化的眼科医生报告了更高的歧视率，晋升到领导层的机会减少，在教师和编辑委员会中的代表性不足。虽然uri匹配率有所提高，但进展并不均衡。亚裔代表人数已经接近平等，而黑人、美洲原住民和太平洋岛民的代表人数仍然严重不足。国家眼科导师项目已经显示出很高的匹配成功率和参与率。实施结构化访谈、整体审查和目标股权策略的住院医师项目报告称，尽管实施情况各不相同，但URiM的代表性有所提高。结论眼科的种族差异仍然普遍存在。虽然总体上取得了进步，但收益集中在亚洲个人身上。迫切需要协调的系统改革，以建立更具代表性，包容性和支持性的眼科专业环境。
{"title":"Racial Disparities in Ophthalmology in Training and Practice: A Systematic Review.","authors":"Angel Gao,Tasha Miller,Arturo Ortin-Martinez,Radha P Kohly","doi":"10.1016/j.ajo.2026.01.008","DOIUrl":"https://doi.org/10.1016/j.ajo.2026.01.008","url":null,"abstract":"TOPICOphthalmology remains one of the least diverse medical specialties, with persistent racial and ethnic disparities throughout training and practice. This review examines experiences of individuals from underrepresented racial minorities (URiM) in ophthalmology within high-income countries, focusing on barriers to representation, discrimination, and equity initiatives.CLINICAL RELEVANCEIdentifying and addressing barriers faced by URiM in ophthalmology is essential to advancing workforce diversity, equitable patient care, and institutional inclusivity. Understanding where inequities persist can inform systemic interventions.METHODSA systematic review of the literature was conducted in MEDLINE, Embase, PsycINFO, CINAHL, Web of Science, and Cochrane Library from inception to November 2024. Eligible studies included English-language publications from 2000 onwards focusing on racial or ethnic minority individuals in ophthalmology. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale and Joanna Briggs Institute Checklist. Data were synthesized descriptively and thematically. The protocol was registered on PROSPERO (CRD42025640520).RESULTS41 eligible studies involving 500,823 responses were included. Most studies were cross-sectional, published after 2021 and conducted in the United States. Across all career stages, URiM individuals were underrepresented and faced structural barriers. In medical school, fewer URiM students pursued ophthalmology, citing lack of mentorship and role models. Minority representation among applicants has increased modestly, particularly among Hispanic students, though overall growth remains limited. During residency and fellowship, racial disparities persisted in research access, fellowship application outcomes, and interview offers. URiM trainees reported negative experiences related to program culture and inclusivity. In practice, racialized ophthalmologists reported higher discrimination rates, reduced advancement into leadership, and underrepresentation on faculty and editorial boards. While URiM match rates have improved, progress has been uneven. Asian representation has approached parity, while Black, Native American, and Pacific Islander individuals remain severely underrepresented. National ophthalmology mentorship programs have demonstrated high match success and participation. Residency programs that implemented structured interviews, holistic review and targeted equity strategies reported improved URiM representation, though implementation varied.CONCLUSIONRacial and ethnic disparities remain pervasive in ophthalmology. While overall progress has occurred, gains have been concentrated among Asian individuals. Coordinated systemic reforms are urgently needed for a more representative, inclusive, and supportive professional environment in ophthalmology.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"56 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.ajo.2026.01.010
Nathan Kerr,David Lubeck,Keith Barton,Ahmad A Aref,Jason Cheng,Justin Spaulding,Nir Shoham-Hazon,Samuel Thomsen,Shamil Patel,Paul Harasymowycz,Iqbal Ike K Ahmed,Harmanjit Singh,Karl Mercieca
PURPOSETo assess real-world canaloplasty outcomes in glaucoma management using standardized data from an international registry.DESIGNThe iTrack™ Global Data Registry (iTGDR) is an ongoing prospective real-world multicenter observational study on ab-interno canaloplasty with the iTrack™ or iTrack™ Advance (Nova Eye Medical), with or without concomitant cataract surgery.PARTICIPANTSPatients diagnosed with ocular hypertension or glaucoma (excluding angle-closure glaucoma).METHODSAnalysis included eyes with minimum 12 months follow-up from the iTGDR. Both standalone canaloplasty and canaloplasty combined with cataract surgery were included. Intraocular pressure (IOP) and glaucoma medications use were assessed at baseline and postoperative follow-ups. Surgical success was defined according to the 2024 American Academy of Ophthalmology (AAO) criteria.MAIN OUTCOME MEASURESIOP, number of glaucoma medications and success rate at last follow-up (LFU).RESULTSTwo hundred and fifty-four patients (344 eyes) were followed over a mean of 20.5±7.9 months (LFU). Following combined canaloplasty and phacoemulsification (n=313 eyes), mean IOP and medication usage reduced from 17.2±5.3 mmHg and 2.1±1.1 preoperatively to 14.1±3.9 mmHg and 1.3±1.4 at LFU (p<0.001); 61.9% of all combined eyes achieved success (increasing to 83% in eyes with baseline IOP >18mmHg), while 43% of eyes became medication-free (versus 7% preoperatively). Standalone canaloplasty (n=24 eyes) reduced IOP and medication usage from 20.2±7.1 mmHg and 2.3±0.9 to 15.3±6.3 mmHg and 1.5±1.6 (p<0.01); 35% of eyes achieved success, and 46% of eyes became medication-free (versus none preoperatively). IOP and medication reductions were significant across glaucoma subtypes (primary and secondary open-angle glaucoma, ocular hypertension) and severities (p<0.01 for all). The rate of additional glaucoma procedure was 4.9%, including laser procedures; no canaloplasty-related sight-threatening complications were reported. A loss of ≥2 lines of corrected distance visual acuity occurred in 7.3% of eyes, most commonly in association with pre-existing advanced disease or unrelated ocular comorbidities.CONCLUSIONIn real-world clinical practice, iTrack canaloplasty significantly reduced IOP and medication burden with a favorable safety profile when performed alone or with phacoemulsification and in diverse glaucoma populations.
{"title":"A Prospective, Real-World, Multicenter Study to Support the Role of Ab-Interno Canaloplasty in Glaucoma Management.","authors":"Nathan Kerr,David Lubeck,Keith Barton,Ahmad A Aref,Jason Cheng,Justin Spaulding,Nir Shoham-Hazon,Samuel Thomsen,Shamil Patel,Paul Harasymowycz,Iqbal Ike K Ahmed,Harmanjit Singh,Karl Mercieca","doi":"10.1016/j.ajo.2026.01.010","DOIUrl":"https://doi.org/10.1016/j.ajo.2026.01.010","url":null,"abstract":"PURPOSETo assess real-world canaloplasty outcomes in glaucoma management using standardized data from an international registry.DESIGNThe iTrack™ Global Data Registry (iTGDR) is an ongoing prospective real-world multicenter observational study on ab-interno canaloplasty with the iTrack™ or iTrack™ Advance (Nova Eye Medical), with or without concomitant cataract surgery.PARTICIPANTSPatients diagnosed with ocular hypertension or glaucoma (excluding angle-closure glaucoma).METHODSAnalysis included eyes with minimum 12 months follow-up from the iTGDR. Both standalone canaloplasty and canaloplasty combined with cataract surgery were included. Intraocular pressure (IOP) and glaucoma medications use were assessed at baseline and postoperative follow-ups. Surgical success was defined according to the 2024 American Academy of Ophthalmology (AAO) criteria.MAIN OUTCOME MEASURESIOP, number of glaucoma medications and success rate at last follow-up (LFU).RESULTSTwo hundred and fifty-four patients (344 eyes) were followed over a mean of 20.5±7.9 months (LFU). Following combined canaloplasty and phacoemulsification (n=313 eyes), mean IOP and medication usage reduced from 17.2±5.3 mmHg and 2.1±1.1 preoperatively to 14.1±3.9 mmHg and 1.3±1.4 at LFU (p<0.001); 61.9% of all combined eyes achieved success (increasing to 83% in eyes with baseline IOP >18mmHg), while 43% of eyes became medication-free (versus 7% preoperatively). Standalone canaloplasty (n=24 eyes) reduced IOP and medication usage from 20.2±7.1 mmHg and 2.3±0.9 to 15.3±6.3 mmHg and 1.5±1.6 (p<0.01); 35% of eyes achieved success, and 46% of eyes became medication-free (versus none preoperatively). IOP and medication reductions were significant across glaucoma subtypes (primary and secondary open-angle glaucoma, ocular hypertension) and severities (p<0.01 for all). The rate of additional glaucoma procedure was 4.9%, including laser procedures; no canaloplasty-related sight-threatening complications were reported. A loss of ≥2 lines of corrected distance visual acuity occurred in 7.3% of eyes, most commonly in association with pre-existing advanced disease or unrelated ocular comorbidities.CONCLUSIONIn real-world clinical practice, iTrack canaloplasty significantly reduced IOP and medication burden with a favorable safety profile when performed alone or with phacoemulsification and in diverse glaucoma populations.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"30 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.ajo.2026.01.012
Zoë R Williams,Rachelle Morgenstern,Asala N Erekat,David Szanto,Michael Wall,Neil R Miller,Leonard A Levin,Brian Woods,Mark J Kupersmith,
OBJECTIVETo report the true frequency and risk factors for acute NAION progression and identify modifiable features to reduce vision worsening.DESIGNSecondary case-control analysis of the QRK207 multicenter, double-masked, sham-controlled, randomized clinical trial.SUBJECTSWe analyzed 599 study eyes with acute NAION (of 729 individuals prospectively enrolled in the QRK207 trial) with separate screening and Day 1 (mean 2.5-day interval) evaluations for progression. No participants included in this analysis received treatment. The Month 2 analysis included only the 167 sham-injected study eyes.METHODSVisual outcomes were assessed using best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and standardized automated perimetry.MAIN OUTCOME MEASURESWe defined progression as ≥10 ETDRS letter loss (also analyzed ≥15 ETDRS letter loss) or worsening of censored corrected average total deviation (avgTD) using quantile regression to define progression and recovery thresholds. We evaluated systemic and ophthalmic features associated with progression.RESULTSFrom screening to Day 1, 7.3% (43/583) eyes had ≥10 ETDRS letter loss and 4.1% eyes had ≥15 ETDRS letter loss. Diabetes mellitus, hypertension, hyperlipidemia (HLD), and cardiovascular risk factors did not increase risk of progression. Previous fellow-eye (FE) NAION and obstructive sleep apnea (OSA) were significantly associated with ≥10 ETDRS letter loss. Only FE NAION remained a risk factor ≥ 15 ETDRS letter loss. Of the 167 sham-injected eyes with screening to Month 2 evaluation, 21.6% (36/167) had ≥10 ETDRS letter loss and 14.4% (24/167) had ≥15 ETDRS letter loss. 91.6% of eyes (33/36) progressed within 22 days of symptom onset (by Day 8). Of the 139 sham-injected eyes with Day 1 to Month 2 evaluation, 18.7% had ≥10 ETDRS letter loss and 13.7% had ≥15 ETDRS letter loss. TD progression from screening to Day 1 occurred in 32.1% (192/599) eyes, 66.1% remained stable, and 1.8% improved. FE NAION and HLD were associated with TD progression.CONCLUSIONSWorsening of vision in NAION occurs acutely. The results do not support cardiovascular risk factors as important hazard features for NAION progression. The only consistent factor associated with progression for both BCVA and VF loss was previous FE NAION.
{"title":"Progression of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and is Unassociated with Modifiable Risk Factors.","authors":"Zoë R Williams,Rachelle Morgenstern,Asala N Erekat,David Szanto,Michael Wall,Neil R Miller,Leonard A Levin,Brian Woods,Mark J Kupersmith, ","doi":"10.1016/j.ajo.2026.01.012","DOIUrl":"https://doi.org/10.1016/j.ajo.2026.01.012","url":null,"abstract":"OBJECTIVETo report the true frequency and risk factors for acute NAION progression and identify modifiable features to reduce vision worsening.DESIGNSecondary case-control analysis of the QRK207 multicenter, double-masked, sham-controlled, randomized clinical trial.SUBJECTSWe analyzed 599 study eyes with acute NAION (of 729 individuals prospectively enrolled in the QRK207 trial) with separate screening and Day 1 (mean 2.5-day interval) evaluations for progression. No participants included in this analysis received treatment. The Month 2 analysis included only the 167 sham-injected study eyes.METHODSVisual outcomes were assessed using best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and standardized automated perimetry.MAIN OUTCOME MEASURESWe defined progression as ≥10 ETDRS letter loss (also analyzed ≥15 ETDRS letter loss) or worsening of censored corrected average total deviation (avgTD) using quantile regression to define progression and recovery thresholds. We evaluated systemic and ophthalmic features associated with progression.RESULTSFrom screening to Day 1, 7.3% (43/583) eyes had ≥10 ETDRS letter loss and 4.1% eyes had ≥15 ETDRS letter loss. Diabetes mellitus, hypertension, hyperlipidemia (HLD), and cardiovascular risk factors did not increase risk of progression. Previous fellow-eye (FE) NAION and obstructive sleep apnea (OSA) were significantly associated with ≥10 ETDRS letter loss. Only FE NAION remained a risk factor ≥ 15 ETDRS letter loss. Of the 167 sham-injected eyes with screening to Month 2 evaluation, 21.6% (36/167) had ≥10 ETDRS letter loss and 14.4% (24/167) had ≥15 ETDRS letter loss. 91.6% of eyes (33/36) progressed within 22 days of symptom onset (by Day 8). Of the 139 sham-injected eyes with Day 1 to Month 2 evaluation, 18.7% had ≥10 ETDRS letter loss and 13.7% had ≥15 ETDRS letter loss. TD progression from screening to Day 1 occurred in 32.1% (192/599) eyes, 66.1% remained stable, and 1.8% improved. FE NAION and HLD were associated with TD progression.CONCLUSIONSWorsening of vision in NAION occurs acutely. The results do not support cardiovascular risk factors as important hazard features for NAION progression. The only consistent factor associated with progression for both BCVA and VF loss was previous FE NAION.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"460 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-13DOI: 10.1016/j.ajo.2026.01.005
Alex Pham, Jithin Yohannan
{"title":"Reply to Commentary on “Development and Evaluation of an Artificial Intelligence Model to Set Target IOP for Glaucoma”","authors":"Alex Pham, Jithin Yohannan","doi":"10.1016/j.ajo.2026.01.005","DOIUrl":"https://doi.org/10.1016/j.ajo.2026.01.005","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"83 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145961646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.ajo.2025.12.039
Carlos Cifuentes-González, Jorge E. Satizabal-García, Alejandro Tello, Virgilio Galvis
{"title":"Comment on “Effect of Angle Kappa on the Refractive Prediction Accuracy in Cataract Patients After Myopic LASIK/PRK”","authors":"Carlos Cifuentes-González, Jorge E. Satizabal-García, Alejandro Tello, Virgilio Galvis","doi":"10.1016/j.ajo.2025.12.039","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.12.039","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"21 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1016/j.ajo.2025.11.051
Henry Bair MD
{"title":"Comment on Development and Evaluation of an Artificial Intelligence Model to Set Target IOP for Glaucoma","authors":"Henry Bair MD","doi":"10.1016/j.ajo.2025.11.051","DOIUrl":"https://doi.org/10.1016/j.ajo.2025.11.051","url":null,"abstract":"","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"34 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-10DOI: 10.1016/j.ajo.2026.01.003
Mohammad Anas,Andrew C Browning,Hwei Wuen Chan,Margaret Reynolds,Rebecca A Procopio,Omar A Mahroo,Jose S Pulido
The eye can only respond in certain patterned ways to any insult. Because of this, it is important to have a sufficiently broad differential diagnosis that encompasses all possibilities that appear to have a similar phenotype. It is critical to appreciate that mimics of noninfectious posterior uveitis (NIPU) are not merely academic distinctions but carry real clinical consequences. Misdiagnosing an inherited retinal disease (IRD) as NIPU can lead to prolonged exposure to systemic corticosteroids or immunosuppressive therapies without benefit, potentially causing avoidable adverse effects. Conversely, failing to recognize a treatable inflammatory cause can lead to avoidable vision loss.
{"title":"Non-cancerous monogenic mimics of noninfectious posterior uveitis.","authors":"Mohammad Anas,Andrew C Browning,Hwei Wuen Chan,Margaret Reynolds,Rebecca A Procopio,Omar A Mahroo,Jose S Pulido","doi":"10.1016/j.ajo.2026.01.003","DOIUrl":"https://doi.org/10.1016/j.ajo.2026.01.003","url":null,"abstract":"The eye can only respond in certain patterned ways to any insult. Because of this, it is important to have a sufficiently broad differential diagnosis that encompasses all possibilities that appear to have a similar phenotype. It is critical to appreciate that mimics of noninfectious posterior uveitis (NIPU) are not merely academic distinctions but carry real clinical consequences. Misdiagnosing an inherited retinal disease (IRD) as NIPU can lead to prolonged exposure to systemic corticosteroids or immunosuppressive therapies without benefit, potentially causing avoidable adverse effects. Conversely, failing to recognize a treatable inflammatory cause can lead to avoidable vision loss.","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"250 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145956026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：